{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:25Z","timestamp":1786998325487,"version":"build-2736575974"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xphs.2024.11.002","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:01:46Z","timestamp":1731128506000},"page":"719-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combating pharmaceutical folklore: No alkyl-sulfonate impurities formed during the synthesis of sulfonate salts"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-2996","authenticated-orcid":false,"given":"David J.","family":"Snodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2024.11.002_bib0001","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/acs.cgd.0c01427","article-title":"Advanced Methodologies for Pharmaceutical Salt Synthesis","volume":"21","author":"Hossain Mithu","year":"2021","journal-title":"Crystal Growth & Design"},{"issue":"7","key":"10.1016\/j.xphs.2024.11.002_bib0002","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/molecules23071719","article-title":"Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations","volume":"23","author":"Gupta","year":"2018","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.xphs.2024.11.002_bib0003","first-page":"555","article-title":"Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole","volume":"68","author":"Paulekuhn","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2024.11.002_bib0004","article-title":"Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts","volume":"607","author":"Bharate","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2024.11.002_bib0005","unstructured":"PubChem. Acetic acid. Dissociation constant: Acetic Acid | CH3COOH | CID 176 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0006","unstructured":"PubChem. Benzoic acid. Dissociation constant: Benzoic Acid | C6H5COOH | CID 243 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0007","unstructured":"PubChem. Methanesulfonic acid. Dissociation constant. Methanesulfonic Acid | CH4O3S | CID 6395 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0008","unstructured":"Chemistry Libre Texts. Acid Strength and pKa - Chemistry LibreTexts Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0009","unstructured":"PubChem. Methylamine dissociation constant: Methylamine | CH3NH2 | CID 6329 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0010","unstructured":"PubChem. Aniline dissociation constant: Aniline | C6H5NH2 | CID 6115 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1177391X0700100003","article-title":"The pKa Distribution of Drugs: Application to Drug Discovery","volume":"1","author":"Manallack","year":"2007","journal-title":"Perspect Medicin Chem"},{"key":"10.1016\/j.xphs.2024.11.002_bib0012","unstructured":"Chemistry Libre Texts. Titration of a Weak Base with a Strong Acid - Chemistry LibreTexts Accessed on 11th October 2024."},{"issue":"2","key":"10.1016\/j.xphs.2024.11.002_bib0013","first-page":"88","article-title":"GC and GC-MS Detection of Alkyl Mesylates in Active Pharmaceutical Ingredients","volume":"46","author":"Balaji","year":"2017","journal-title":"Int J Pharm Sci Rev Res"},{"key":"10.1016\/j.xphs.2024.11.002_bib0014","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11094-016-1367-4","article-title":"Modern Approaches to Estimating the Content of Genotoxic Impurities in Drugs (a Review)","volume":"49","author":"Matveeva","year":"2016","journal-title":"Pharm Chem J"},{"issue":"3","key":"10.1016\/j.xphs.2024.11.002_bib0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.31788\/RJC.2020.1335819","article-title":"LC-MS\/MS Method for the Trace Level Determination of Ethyl Benzene Sulfonate: a Genotoxic Impurity in Amlodipine Besylate","volume":"13","author":"Mullangi","year":"2020","journal-title":"Rasayan J Chem"},{"key":"10.1016\/j.xphs.2024.11.002_bib0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5173(00)00350-1","article-title":"Salt form selection and characterization of LY333531 mesylate monohydrate","volume":"198","author":"Engel","year":"2000","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.xphs.2024.11.002_bib0017","unstructured":"EMA 2023 ICH M7(R2) Questions and Answers on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0018","unstructured":"ECHA Pleuromutilin-22-mesilate mutagenicity Registration Dossier - ECHA (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0019","unstructured":"ECHA 1-bromopentane mutagenicity Registration Dossier - ECHA (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0020","unstructured":"ECHA 1-bromohexane mutagenicity https:\/\/echa.europa.eu\/registration-dossier\/-\/registered-dossier\/10829\/7\/7\/2 Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0021","unstructured":"VEGA QSAR VEGA QSAR \u2013 VEGA HUB Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0022","unstructured":"ECHA 1-bromodecane mutagenicity Registration Dossier - ECHA (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0023","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1158\/0008-5472.CAN-06-4061","article-title":"Mechanistic Influences for Mutation Induction Curves after Exposure to DNA-Reactive Carcinogens","volume":"67","author":"Doak","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.xphs.2024.11.002_bib0024","doi-asserted-by":"crossref","first-page":"59795","DOI":"10.18632\/oncotarget.10928","article-title":"Poor recognition of O6-isopropyl dG by MGMT triggers double strand break-mediated cell death and micronucleus induction in FANC-deficient cells","volume":"7","author":"Hashimoto","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xphs.2024.11.002_bib0025","unstructured":"Pharmeuropa 2000;12.1 Enquiry p27 Pharmeuropa Online (edqm.eu) Accessed on 11th October 2024"},{"key":"10.1016\/j.xphs.2024.11.002_bib0026","series-title":"M.Sc. thesis","author":"Ahmad","year":"2002"},{"key":"10.1016\/j.xphs.2024.11.002_bib0027","unstructured":"Pharmeuropa 2004;16.1 Pharmeuropa Online (edqm.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0028","unstructured":"FDA 2005 Chemistry Review for Doxazosin Mesylate. eCopy, Inc. (fda.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1021\/op800192a","article-title":"Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation","volume":"13","author":"Teasdale","year":"2009","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/op900301n","article-title":"A Detailed Study of Sulfonate Ester Formation and Solvolysis Reaction Rates and Application toward Establishing Sulfonate Ester Control in Pharmaceutical Manufacturing Processes","volume":"14","author":"Teasdale","year":"2010","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0031","unstructured":"Chemistry LibreTexts. Hydroxyl group substitution. Hydroxyl Group Substitution - Chemistry LibreTexts Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0032","unstructured":"Socratic Q&A. Organic Chemistry. Are triflate, tosylate and mesylate nucleophilic? Are triflate, tosylate and mesylate nucleophilic? | Socratic Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.dyepig.2020.108726","article-title":"A convenient approach to arenediazonium tosylates","volume":"184","author":"Mihela\u010d","year":"2021","journal-title":"Dyes and Pigments"},{"key":"10.1016\/j.xphs.2024.11.002_bib0034","unstructured":"Ashenhurst, J. Master Organic Chemistry. Alcohols \u2013 acidity and basicity, https:\/\/www.masterorganicchemistry.com\/2014\/10\/17\/alcohols-acidity-and-basicity\/ Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0035","unstructured":"EMA 2023 ICH M7(R2) Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. EMA\/CHMP\/ICH\/83812\/2013. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m7r2-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf Accessed on 11th October 2024. Accessed on 11th October 2024"},{"key":"10.1016\/j.xphs.2024.11.002_bib0036","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/op900242x","article-title":"Application of Quality by Design Principles to Support Development of a Control Strategy for the Control of Genotoxic Impurities in the Manufacturing Process of a Drug Substance","volume":"14","author":"Cimarosti","year":"2009","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0037","unstructured":"Smith G, Cordova R, Chen JCH et al. Removal of alkyl alkanesulfonate esters from alkanesulfonic acids and other organic media; Arkema patent 2007 US7297813B2 - Removal of alkyl alkanesulfonate esters from alkanesulfonic acids and other organic media - Google Patents Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0038","unstructured":"BASF European Patent Application 2021 https:\/\/data.epo.org\/publication-server\/rest\/v1.0\/publication-dates\/20210113\/patents\/EP3763701NWA1\/document.pdf Accessed on 11th October 2024"},{"key":"10.1016\/j.xphs.2024.11.002_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s40831-022-00641-6","article-title":"Methanesulfonic Acid (MSA) in Hydrometallurgy","volume":"9","author":"Binnemans","year":"2022","journal-title":"J Sustain Metall"},{"key":"10.1016\/j.xphs.2024.11.002_bib0040","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1126\/science.aav0177","article-title":"Activation of methane: A selective industrial route to methanesulfonic acid","volume":"363","author":"D\u00edaz-Urrutia","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xphs.2024.11.002_bib0041","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/op500397h","article-title":"Mutagenic Alkyl-Sulfonate Impurities in Sulfonic Acid Salts: Reviewing the Evidence and Challenging Regulatory Perceptions","volume":"19","author":"Snodin","year":"2015","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0042","unstructured":"Arkema AMSA. Anhydrous Methanesulfonic Acid. https:\/\/www.arkema.com\/global\/en\/products\/product-finder\/product\/thiochemicals\/sulfonyls\/amsa\/ Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0043","unstructured":"Lutropur MSA 100. https:\/\/static1.squarespace.com\/static\/54f0b505e4b017cb0d7a6f26\/t\/55f9b1a3e4b09474af30c6dc\/1442427299178\/MSA+100+SDS.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0044","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-6405-6-18","article-title":"Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept\u00ae, Roche): overview","volume":"6","author":"Pozniak","year":"2009","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.xphs.2024.11.002_bib0045","unstructured":"FDA 1997 Approval package for Viracept oral powder, 50 mg\/g. pkz72b5.tmp (fda.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0046","unstructured":"CHMP 2007 Assessment Report for Viracept EMEA\/CHMP\/492059\/2007. viracept-h-c-164-z-109-epar-assessment-report-lifting-suspension_en.pdf (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0047","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.toxlet.2009.02.020","article-title":"What happened: The chemistry side of the incident with EMS contamination in Viracept tablets","volume":"190","author":"Gerber","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.xphs.2024.11.002_bib0048","unstructured":"Cayman Chemical Company 2022. Nelfinavir mesylate. Product Information. 15144.pdf (caymanchem.com) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0049","unstructured":"Chemistry LibreTexts. Nucleophilic Substitution Reactions of Alcohols- Forming Alkyl Halides. https:\/\/chem.libretexts.org\/Bookshelves\/Organic_Chemistry\/Map%3A_Organic_Chemistry_(Bruice)\/10%3A_Reactions_of_Alcohols_Ethers_Epoxides_Amine_and_Sulfur-_Containing_Compounds\/10.01%3A_Nucleophilic_Substitution_Reactions_of_Alcohols-_Forming_Alkyl_Halides Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0050","unstructured":"EMEA\/CMDh 2008 Request to Assess the Risk of Occurrence of Contamination with Mesilate Esters and Related Compounds in Pharmaceuticals. EMEA\/CMDh\/98694\/2008 https:\/\/www.hma.eu\/uploads\/media\/CMDh_Letter_for_all_MAHs_for_MPs_containing_active_ingredients_in_the_form_of_Mesilates__Isetionates__Tosilates_or_Besilates.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0051","unstructured":"TGA 2013;18.2.6 Impurities relating to mesilates, tosilates, (di)isetionate and besilates. Guidance 18: Impurities in drug substances and drug products (tga.gov.au) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0052","unstructured":"CMDh 2008 Product-related advice: Heads of Medicines Agencies: Product-related advice (hma.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0053","unstructured":"EDQM 2023 MSL Working Party: https:\/\/www.edqm.eu\/en\/groups-of-experts-and-working-parties Accessed on 11th October 2024"},{"key":"10.1016\/j.xphs.2024.11.002_bib0054","unstructured":"EDQM 2016 Press Release. Potential presence of mutagenic alkyl sulfonates in active substances. https:\/\/www.edqm.eu\/en\/d\/182276 Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0055","unstructured":"CVMP 2015 Committee for Medicinal Products for Veterinary Use. Minutes of the 4\u22126 November 2015 meeting, Dec 8, 2015; EMA\/CVMP\/829802\/2015. Committee for Medicinal Products for Veterinary Use Minutes of the 4-6 November 2015 meeting (europa.eu) Accessed on 11th October 2024"},{"key":"10.1016\/j.xphs.2024.11.002_bib0056","unstructured":"Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients. ICH Q7 https:\/\/www.ema.europa.eu\/en\/ich-q7-good-manufacturing-practice-active-pharmaceutical-ingredients-scientific-guideline Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0057","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.toxlet.2009.03.015","article-title":"Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate","volume":"190","author":"M\u00fcller","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.xphs.2024.11.002_bib0058","unstructured":"British Pharmacopoeia 2023 EAG BPC Minutes. EAG BPC minutes - British Pharmacopoeia Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0059","unstructured":"British Pharmacopoeia Commission 2024 Alkyl Sulfonate Ester Impurities. COM(21)39. https:\/\/assets.publishing.service.gov.uk\/media\/669e2377fc8e12ac3edb00d4\/Meeting_Papers_mesilates_only_redacted.pdf Accessed on 11th October 2024."},{"issue":"4","key":"10.1016\/j.xphs.2024.11.002_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2345\/0899-8205-57.4.163","article-title":"Principles of Parametric Release: Emphasis on Data Collection and Interpretation","volume":"57","author":"McEvoy","year":"2023","journal-title":"Biomedical Instrumentation & Technology"},{"key":"10.1016\/j.xphs.2024.11.002_bib0061","first-page":"574","article-title":"Bestimmung von Alkylsulfons\u00e4ureestern in Mesilat- bzw. Besilatsalz-haltigen Arzneimitteln mittels GC\/MS bzw","volume":"73","author":"Wollein","year":"2011","journal-title":"LC\/MS. Pharmazeutische Industrie"},{"key":"10.1016\/j.xphs.2024.11.002_bib0062","unstructured":"Americanbio 2015 Acetonitrile, safety data sheet. https:\/\/www.americanbio.com\/sites\/default\/files\/sds\/AB00120.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0063","doi-asserted-by":"crossref","unstructured":"Britt PF. 2002 Pyrolysis and Combustion of Acetonitrile (CH3CN) ORNL\/TM-2002\/113. https:\/\/info.ornl.gov\/sites\/publications\/Files\/Pub57226.pdf","DOI":"10.2172\/814574"},{"key":"10.1016\/j.xphs.2024.11.002_bib0064","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejps.2011.11.008","article-title":"Simultaneous determination of alkyl mesilates and alkyl besilates in finished drug products by direct injection GC\/MS","volume":"45","author":"Wollein","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.11.002_bib0065","first-page":"1","article-title":"Simultaneous Determination of 15 Sulfonate Ester Impurities in Phentolamine Mesylate, Amlodipine Besylate, and Tosufloxacin Tosylate by LC-APCI-MS\/MS","author":"Jin","year":"2019","journal-title":"J Anal Methods Chem"},{"key":"10.1016\/j.xphs.2024.11.002_bib0066","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/op300216x","article-title":"An Approach to Control Strategies for Sulfonate Ester Formation in Pharmaceutical Manufacturing Based on Recent Scientific Understanding","volume":"16","author":"Elder","year":"2012","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0067","unstructured":"EMEA 2008 CHMP Assessment Report for Pradaxa. EMEA\/174363\/2008. Pradaxa, INN- dabigatran etexilate (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0068","unstructured":"TGA 2016 Australian Product Information for Pradaxa AusPAR Attachment 1: Product Information for Pradaxa (tga.gov.au) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0069","unstructured":"Ferrari M, DeZani D, Valentincic M et al. 2015 International Patent for synthesis of dabigatran etexilate mesilate. WO 2015\/124764 A1. WO2015124764A1.pdf (storage.googleapis.com) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0070","unstructured":"EMA 2021 Pradaxa. Variation Assessment. EMA\/145360\/2021. Pradaxa, INN-dabigatran etexilate (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0071","first-page":"1","article-title":"How Bulky of Base Adducts can be Responsible for Clastogenicity rather than Mutagenicity?","volume":"8","author":"Kikuchi","year":"2023","journal-title":"ACT"},{"key":"10.1016\/j.xphs.2024.11.002_bib0072","unstructured":"EMA 2020 Roclanda Assessment Report. EMA\/CHMP\/637805\/2020 https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/roclanda-epar-public-assessment-report_en.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0073","unstructured":"PubChem. p-Toluenesulfonic acid. Dissociation constant. p-Toluenesulfonic acid | C7H7SO3H | CID 6101 - PubChem (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0074","unstructured":"Lohray B, Lohray V, Dave MG et al. 2015 Salts of Clopidogrel besylate and process for preparation. European patent EP2865681A2. https:\/\/patentimages.storage.googleapis.com\/df\/0c\/59\/f8768a851971de\/EP2865681A2.pdf Accessed on 11th October 2024."},{"issue":"2","key":"10.1016\/j.xphs.2024.11.002_bib0075","first-page":"145","article-title":"Determination of Potential Genotoxic Impurities in Sorafenib Tosylate by UPLC Method","volume":"4","author":"Yadav","year":"2012","journal-title":"IJTAS"},{"key":"10.1016\/j.xphs.2024.11.002_bib0076","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3797\/scipharm.1106-23","article-title":"A Sensitive and Simple HPLC-UV Method for Trace Level Quantification of Ethyl p-Toluenesulfonate and Methyl p-Toluenesulfonate, Two Potential Genotoxins in Active Pharmaceutical Ingredients","volume":"79","author":"Nageswari","year":"2011","journal-title":"Sci Pharm"},{"key":"10.1016\/j.xphs.2024.11.002_bib0077","unstructured":"Japanese Pharmacopoeia 2016 JP17_REV_1.pdf (mhlw.go.jp) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0078","unstructured":"Personal communication 2019 EDQM Director Dr Susanne Keitel"},{"issue":"6","key":"10.1016\/j.xphs.2024.11.002_bib0079","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/molecules27061950","article-title":"Determination of Methyl Methanesulfonate and Ethyl Methylsulfonate (sic) in New Drug for the Treatment of Fatty Liver Using Derivatization Followed by High-Performance Liquid Chromatography with Ultraviolet Detection","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2024.11.002_bib0080","unstructured":"Drugbank. Doxazosin mesylate: Doxazosin mesylate | DrugBank Online Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0081","unstructured":"Cordis \u2013 EU research results. Ultrafast Structural Dynamics of Elementary Water-Mediated Proton Transport Processes. https:\/\/cordis.europa.eu\/project\/id\/788704 Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0082","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00216-003-2020-0","article-title":"Determination of protonation constants of some fluorinated polyamines by means of 13 C NMR data processed by the new computer program HypNMR2000. Protonation sequence in polyamines","volume":"376","author":"Frassineti","year":"2003","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"10.1016\/j.xphs.2024.11.002_bib0083","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1081\/SL-120014937","article-title":"Study Of The Protonation\/Deprotonation Sequence Of Two Polyamines: Bis-[(2s)-2-Pyrrolidinylmethyl] Ethylenediamine And Spermidine By1h And13c Nuclear Magnetic Resonance","volume":"35","author":"Alves da Silva","year":"2002","journal-title":"Spectrosc Lett"},{"key":"10.1016\/j.xphs.2024.11.002_bib0084","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1432-1033.1983.tb07164.x","article-title":"Determination of Protonation Sites in Thermospermine and in Some Other Polyamines by 15N and 13C Nuclear Magnetic Resonance Spectroscopy","volume":"130","author":"Takeda","year":"1983","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.xphs.2024.11.002_bib0085","unstructured":"Williams R. 2022 Compilation of pKa data. https:\/\/organicchemistrydata.org\/hansreich\/resources\/pka\/pka_data\/pka-compilation-williams.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0086","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/ja01200a068","article-title":"Kinetics and Mechanism of the Reaction of Hydrogen Bromide with Ethanol","volume":"69","author":"Grunwald","year":"1947","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.xphs.2024.11.002_bib0087","unstructured":"Wockhardt Ltd. 2006 Process for the manufacture of citalopram hydrobromide. International Publication No. WO 2005\/042473 A1 US Patent Application for Process for the manufacture of citalopram hydrobromide Patent Application (Application #20060293530 issued December 28, 2006) - Justia Patents Search Accessed on 11th October 2024."},{"issue":"1","key":"10.1016\/j.xphs.2024.11.002_bib0088","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41598-023-28825-4","article-title":"Carcinogenicity and testicular toxicity of 2-bromopropane in a 26-week inhalation study using the rasH2 mouse model","volume":"13","author":"Goto","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2024.11.002_bib0089","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2024.11.002_bib0090","unstructured":"EMA 2023 Carcinogenic Potency Categorisation Approach for N-nitrosamines. EMA\/451665\/2023. Appendix 2 (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0091","unstructured":"FDA 2024 Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cder-nitrosamine-impurity-acceptable-intake-limits Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0092","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1248\/cpb.c20-00380","article-title":"Development of a Logic Model for Promoting Incorporation of the Concepts of Impurity-Related ICH Guidelines into Pharmacopoeias Based on Cause and Effect Analysis","volume":"68","author":"Matsuhama","year":"2020","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.xphs.2024.11.002_bib0093","unstructured":"Rosen J. The Science of Climate Change Explained: Facts, Evidence and Proof. The New York Times 2021. The Science of Climate Change Explained: Facts, Evidence and Proof - The New York Times (nytimes.com) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0094","series-title":"Alkyl Mesylate Formation Studies Using Pharmaceutically Relevant Conditions","author":"Birch","year":"2012"},{"key":"10.1016\/j.xphs.2024.11.002_bib0095","article-title":"Where's the evidence? Policies based on false hypotheses can persist in spite of overwhelming contradictory data","author":"Snodin","year":"2020","journal-title":"Chemistry World"},{"key":"10.1016\/j.xphs.2024.11.002_bib0096","first-page":"23","article-title":"Structure\u2013activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters","volume":"581","author":"Glowienke","year":"2005","journal-title":"MRGTEM"},{"key":"10.1016\/j.xphs.2024.11.002_bib0097","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0165-1110(84)90007-1","article-title":"Sega GA A review of the genetic effects of ethyl methanesulfonate","volume":"134","year":"1984","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"10.1016\/j.xphs.2024.11.002_bib0098","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.3390\/ijms22147461","article-title":"The Alkylating Agent Methyl Methanesulfonate Triggers Lipid Alterations at the Inner Nuclear Membrane That Are Independent from Its DNA-Damaging Ability","volume":"22","author":"Ovejero","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.xphs.2024.11.002_bib0099","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.toxlet.2009.03.016","article-title":"Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate","volume":"190","author":"Gocke","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.xphs.2024.11.002_bib0100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/em.21910","article-title":"Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28-day studies","volume":"56","author":"Coffing","year":"2014","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.xphs.2024.11.002_bib0101","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acs.oprd.8b00397","article-title":"Elusive Impurities - Evidence versus Hypothesis. Technical and Regulatory Update on Alkyl Sulfonates in Sulfonic Acid Salts","volume":"23","author":"Snodin","year":"2019","journal-title":"Org Process Res Dev"},{"issue":"1","key":"10.1016\/j.xphs.2024.11.002_bib0102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41021-021-00206-1","article-title":"Bacterial mutagenicity test data: collection by the task force of the Japan pharmaceutical manufacturers association","volume":"43","author":"Hakura","year":"2021","journal-title":"Genes and Environ"},{"key":"10.1016\/j.xphs.2024.11.002_bib0103","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1021\/acs.oprd.2c00182","article-title":"Novel Analytical Approach to Quantify Reactive Potentially Mutagenic Sulfonate Ester Impurities in Pharmaceutical Compounds and Its Application in the Development of a Control Strategy for Nonaflate Impurities in Belzutifan Synthesis","volume":"26","author":"Gangam","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"1","key":"10.1016\/j.xphs.2024.11.002_bib0104","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3123\/jemsge.2013.012","article-title":"Role of Nucleotide Excision Repair or Base Excision Repair in Movement of various n-Alkylated Bases, Investigated by the Comet Assay","volume":"36","author":"Odajima","year":"2014","journal-title":"Genes and Environ"},{"key":"10.1016\/j.xphs.2024.11.002_bib0105","unstructured":"Report on Carcinogens 2021 Methyl Methanesulfonate. RoC Profile: Methyl Methanesulfonate; 15th RoC 2021 (nih.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0106","unstructured":"The Carcinogenic Potency Database (CPDB) https:\/\/files.toxplanet.com\/cpdb\/index.html Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0107","series-title":"Comparative Chemical Mutagenesis","first-page":"743","article-title":"Comparative Mutagenicity of Methyl Methanesulfonate and Ethyl Methanesulfonate","author":"Kondo","year":"1981"},{"key":"10.1016\/j.xphs.2024.11.002_bib0108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.toxlet.2009.04.031","article-title":"General 4-week toxicity study with EMS in the rat","volume":"190","author":"Pfister","year":"2009","journal-title":"Toxicol Lett"},{"issue":"4","key":"10.1016\/j.xphs.2024.11.002_bib0109","first-page":"253","article-title":"In vitro reactions of isopropyl methanesulfonate with DNA and with 2\u2019-deoxyribonucleosides","volume":"11","author":"Li","year":"1990","journal-title":"Cancer Biochem Biophys"},{"key":"10.1016\/j.xphs.2024.11.002_bib0110","unstructured":"LHASA Carcinogenicity Database. Bromomethane. Lhasa Carcinogenicity Database - Study Information (lhasalimited.org) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0111","unstructured":"ATSDR Toxicological Profile for Bromomethane 2020. ATSDR Bromomethane Tox Profile (cdc.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0112","unstructured":"EMA 2023 ICH M7(R2) Questions and Answers on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. ICH M7(R2) Questions and Answers on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0113","unstructured":"LHASA Carcinogenicity Database. Bromoethane. Lhasa Carcinogenicity Database - Study Information (lhasalimited.org) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0114","unstructured":"EMA 2023 Committee for Medicinal Products for Human Use ICH M7(R2) Addendum on application of the principles of the ICH M7 guideline to calculation of compound-specific acceptable intakes. EMA\/CHMP\/ICH\/502766\/2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m7r2-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable-intakes-step-5_en.pdf Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.yrtph.2018.02.001","article-title":"Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides","volume":"94","author":"Bercu","year":"2018","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2024.11.002_bib0116","unstructured":"FDA 1997 Approval package for Viracept oral powder, 50 mg\/g. pkz72b5.tmp (fda.gov) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0117","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.toxlet.2009.04.003","article-title":"Ethyl methanesulfonate toxicity in Viracept - A comprehensive human risk assessment based on threshold data for genotoxicity","volume":"190","author":"M\u00fcller","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.xphs.2024.11.002_bib0118","unstructured":"EMEA 2008 Questions and answers on the follow-up to the contamination of Viracept (nelfinavir) with ethyl mesilate. EMEA\/CHMP\/375807\/2008. London, 24 July 2008 (europa.eu) Accessed on 11th October 2024."},{"key":"10.1016\/j.xphs.2024.11.002_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115880","article-title":"The quality of drugs and drug products - Always guaranteed?","volume":"239","author":"Buschmann","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2024.11.002_fur1","series-title":"Genotoxic Impurities. Strategies for Identification and Control","first-page":"385","article-title":"Mechanism and processing parameters affecting the formation of sulfonate esters: summary of the Product Quality Research Institute studies","author":"Teasdale","year":"2010"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924005094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924005094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T18:06:51Z","timestamp":1742666811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924005094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0022354924005094"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.11.002","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combating pharmaceutical folklore: No alkyl-sulfonate impurities formed during the synthesis of sulfonate salts","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}